Trace Neuroscience vs Insilico Medicine
Side-by-side comparison of AI visibility scores, market position, and capabilities
Launched with $101M Series A (Third Rock, Atlas, GV, RA Capital). TRCN-1023 (ASO for UNC13A mRNA splicing) entered ALS clinical testing in early 2026 — skipping healthy volunteer phase. Targets 97% of ALS patients.
About
Trace Neuroscience launched with $101 million in Series A financing from Third Rock Ventures, Atlas Venture, GV (Google Ventures), and RA Capital Management, developing TRCN-1023 — an antisense oligonucleotide (ASO) that corrects UNC13A mRNA splicing defects that have been genetically validated as a driver of ALS (amyotrophic lateral sclerosis). The company went directly to ALS patient enrollment in early 2026, bypassing the healthy volunteer phase typical of first-in-human trials, reflecting confidence in the mechanism's tolerability profile.
Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS.
About
Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.